ctivation of the renin -angiotensin system (RAS) has a profound effect on the prognosis of patients with myocardial infarction and/or heart failure with reduced ejection fraction (HFREF), as proven by the beneficial effects of angiotensin-converting enzyme inhibitors (ACEIs). 1 Because angiotensin II is produced in the ACE-dependent and -independent pathways, 2 the addition of AT1 receptor blockers (ARBs) to ACEIs is expected to completely block RAS activity and to improve the prognosis of patients with cardiovascular diseases.
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In patients with HFREF, addition of ARB to ACEI reduces mortality and morbidity. 3, 4 The Randomized Evaluation of Strategies for the Left Ventricular Dysfunction (RESOLVD) pilot study demonstrated that the combination of candesartan and enalapril was more effective in the prevention of left ventricular (LV) remodeling than monotherapy with either drug. 5 The current consensus is that ARBs can be considered in combination with ACEIs in HFREF patients who remain symptomatic. The usefulness of combination therapy, however, is controversial in patients with acute myocardial infarction (AMI). The VALIANT study showed that combination therapy with valsartan and captopril and monotherapy with either drug had similar effects on the prognosis of AMI patients complicated by reduced EF, heart failure or both. 6 The effects of the 3 treatment arms on LV functional and structural changes were also similar. 7 Standard therapies in Japan are derived from such evidence obtained in Caucasian subjects. But ethnic differences should be present in the response to pharmacological interventions, and the necessity for evidence relating to Japanese patients has been emphasized. The T-VENTURE Study demonstrated similar effects in the prevention of LV remodeling and clinical events between valsartan and ACEIs in Japanese patients with AMI. 8 In this issue of the Journal, Miyazaki et al have expanded the previous study by prospectively demonstrating that combination therapy with valsartan and trandolapril inhibited LV remodeling compared to monotherapy with either drug in Japanese patients with AMI. 9 This new evidence may be informative for Japanese cardiologists, but we have to stop and consider whether we are allowed to simply conclude that the combination therapy is effective in Japanese patients with AMI.
As shown in Table, there are several critical differences between the subjects in the VALIANT and the Miyazaki et al studies, in addition to the ethnic differences. Patients with severely reduced EF or heart failure were included in the VALIANT study, but not in the Miyazaki et al study. The proportion of patients with revascularization therapy was only 50% in the VALIANT study and was 100% in the Miyazaki et al study. The prescription rate of β-blockers and statins was also different. These differences in patient characteristics might be responsible for the different conclusions.
In addition to the effectiveness of the combination therapy, the frequency of adverse events is another issue. The VALIANT and ONTARGET studies, although the subjects of the ONTARGET study were not AMI patients, reported a higher frequency of adverse events in the combination therapy group. 6, 10 The doses of ACEIs and ARBs in those studies conducted in Western countries were higher than those prescribed in Japan. The dose of ACEI in the combination group was the same as that in the ACEI monotherapy group in both studies, but was reduced to half of the dose of the monotherapy group in the Miyazaki et al study. The principal adverse events were hypotension, renal impairment and hyperkalemia. As the Miyazaki et al study has demonstrated, combination therapy using doses of ACEIs and ARBs approved in Japan may provide additional benefits without an increase in adverse events in AMI patients, if the dose of each drug is reduced as compared to monotherapy.
Another important issue is whether the beneficial and adverse effects of the combination therapy with ARB and ACEI are class effects or not. It is well known that the beneficial effects of β-blockers in patients with HFREF are restricted to some specific β-blockers. Pilote et al showed that the survival benefits in elderly patients with AMI are different depending on the ACEIs prescribed. 11 The VALIANT and Miyazaki et al studies used different ACEIs. The ONTARGET study used another ARB and ACEI. To discuss the beneficial and adverse effects of the combination therapy, we may have to clarify which ACEI and ARB are used.
Miyazaki et al have proposed the mechanisms of the beneficial effects of the combination therapy. They have showed that the combination therapy most suppressed the expression of matrix metalloproteinase-9 (MMP-9). We previously showed that MMP-9 expression was enhanced in a heart fail-
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ure model with LV dilatation as compared to that without LV dilatation despite the same genetic background and the similar MMP-2 expression in the myocardium. 12 The pharmacological inhibition of RAS prevented LV dilatation and MMP-9 expression. 13 The MMP-9-guide therapy may be useful to determine the doses of medications required to obtain beneficial effects without adverse events in patients with AMI.
To clarify the efficacy of the combination therapy with ACEIs and ARBs for Japanese patients with AMI, future studies need to address at least the following issues: which patients receive the benefits from the combination therapy; which ACEI and ARB and which dose should be combined; and what is an appropriate marker to determine the dose. It may be inappropriate to ask a simple question as to whether the combination therapy with ACEIs and ARBs is effective or not in Japanese patients with AMI.
